Search clinical trials for: Post-essential thrombocythemia (PET-MF)

Total 5337 results

Incyte Corporation

Completed

Ruxolitinib (INCB018424) in Participants With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis (PPV-MF)

MPN (Myeloproliferative Neoplasms)

United States
Ajax Therapeutics, Inc.

Not yet recruiting

A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)

Primary Myelofibrosis | Post-Polycythemia Vera Myelofibrosis | PMF | Post-Essential Thrombocythemia Myelofibrosis | PPV-MF | PET-MF

United States
Novartis Pharmaceuticals

Completed

Exploratory Phase II Study of INC424 Patients With Primary Myelofibrosis (PMF) or Post Polycythaemia Myelofibrosis (PPV MF) or Post Essential Thrombocythaemia Myelofibrosis (PET-MF) (MACS2030)

Primary Myelofibrosis (PMF) | Post Polycythaemia Myelofibrosis (PPV MF) | Post Essential Thrombocythaemia Myelofibrosis (PET-MF)

United Kingdom
Incyte Corporation

Completed

Study of Ruxolitinib (INCB018424) Sustained Release Formulation in Myelofibrosis Patients

Myelofibrosis

United States
Novartis Pharmaceuticals

Completed

Panobinostat and Ruxolitinib in Primary Myelofibrosis, Post-polycythemia Vera-myelofibrosis or Post-essential Thrombocythemia-myelofibrosis

Idiopathic Myelofibrosis | Post Essential Thrombocythemia Myelofibrosis | Post Polycythemia-Vera Myelofibrosis

United Kingdom, Ireland, Germany, Italy, France
Imago BioSciences, Inc., a subsidiary of Merck...

Completed

Bomedemstat (IMG-7289/MK-3543) in Participants With Myelofibrosis (IMG-7289-CTP-102/MK-3543-002)

Myelofibrosis | Primary Myelofibrosis (PMF) | Post-polycythemia Vera Myelofibrosis (PPV-MF) | Post-essential Thrombocythemia Myelofibrosis (PET-MF)

Germany, United States, Australia, Italy, United Kingdom
Novartis Pharmaceuticals
Incyte Corporation

Terminated

A Study to Find the Maximum Tolerated Dose of the Experimental Combination of the Drugs INC424 and BKM120 in Patients With Primary or Secondary Myelofibrosis

Myelofibrosis

Spain, United Kingdom, Australia, Israel, Germany, Italy, Singapore, Austria, France
Novartis Pharmaceuticals

Completed

INC424 for Patients With Primary Myelofibrosis, Post Polycythemia Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis. (JUMP)

Myelofibrosis

Belgium, Colombia, Canada, Italy, Spain, Austria, Germany, Czechia, Thailand, Hungary, Greece, Argentina, Brazil, Israel, Russian Federation, Mexico, Portugal, South Africa, Tunisia, Slovakia, Saudi Arabia, Poland, Algeria, Ireland, Mor...
Incyte Corporation

Completed

An Open Label Study of Itacitinib Administered Orally in Patients With Myelofibrosis

MPN (Myeloproliferative Neoplasms)

Canada, United States, Australia
Tung Wah College

Recruiting

Skills Learning and Self-confidence in Learning in High-fidelity Simulation

Satisfaction | Problem-solving | Clinical Reasoning

Hong Kong
Vanderbilt-Ingram Cancer Center

Active, not recruiting

TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea

Polycythemia Vera | Myelofibrosis

United States
AbbVie

Active, not recruiting

A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis (REFINE)

Myelofibrosis (MF)

United States, Australia, Belgium, Bulgaria, Canada, Croatia, France, Greece, Hungary, Israel, Italy, Japan, Korea, Republic of, Poland, Puerto Rico, Russian Federation, Serbia, Spain, Taiwan, Turkey, United Kingdom
Coopervision, Inc.

Completed

Clinical Evaluation of Biofinity Multifocal Compared With Air Optix Aqua Multifocal and With PureVision Multifocal (INNOVATION)

Presbyopia
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Ruxolitinib in the Treatment of Anemic Myelofibrosis Patients. (REALISE)

Primary Myelofibrosis | Post-Essential Thrombocythemia Myelofibrosis | Post-Polycythemia Vera-Myelofibrosis

Belgium, Italy, Spain, Bulgaria, Turkey, Greece, Russian Federation, Austria, Canada, Japan, Germany
Kartos Therapeutics, Inc.

Recruiting

KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment (BOREAS)

Primary Myelofibrosis (PMF) | Post-Polycythemia Vera MF (Post-PV-MF) | Post-Essential Thrombocythemia MF (Post-ET-MF)

United States, Korea, Republic of, Germany, Australia, Hungary, France, Spain, Italy, Taiwan, Thailand, Brazil, Poland, Turkey, Israel, Portugal, Romania, Argentina, Bulgaria, Canada, Croatia, Czechia, Lithuania, Mexico, Philippines, United... and more
Purdue University

Not yet recruiting

The Effects of 12-Week High-intensity Interval Training With Mindfulness-based Recovery on Executive Function, Fitness, and Mindfulness in Children

Healthy Volunteers

United States
Purdue University
University of Oregon

Not yet recruiting

Acute Effects of High-intensity Interval Training With Mindfulness-based Recovery on Executive Function in Children

Healthy Volunteers
Bausch & Lomb Incorporated

Completed

A Study to Evaluate a Mid Add Multi-Focal Soft Contact Lens

Presbyopia

United States
National Taiwan University Hospital

Unknown

Application of Integrated MR-PET in Patients With Gynecologic Cancers

MR-PET Imaging

Taiwan
Novartis Pharmaceuticals

Withdrawn

Study of Select Combinations in Adults With Myelofibrosis

Primary Myelofibrosis | Myelofibrosis | Post-Polycythemia Vera Myelofibrosis | PMF | Post-Essential Thrombocythemia Myelofibrosis
Campus Bio-Medico University
University of Rome Tor Vergata; University Hospital of Ferrara; Arcispedale Santa... and other collaborators

Terminated

Low-frequency Pulsed Electromagnetic Fields (ELF-MF) as Treatment for Acute Ischemic Stroke (I-NIC)

Ischemic Stroke | Stroke, Acute

Italy
VA Office of Research and Development

Not yet recruiting

Type I Hybrid Effectiveness-Implementation Trial of Primary Care Brief Mindfulness Training for Veterans

Depression | Anxiety | Post Traumatic Stress Disorder (PTSD)

United States
Centre Georges Francois Leclerc

Active, not recruiting

Study Evaluating the Utility of 18F-FDG PET in Assessing Early Response to Neoadjuvant Chemotherapy in Patients With Mammary Gland Cancer (TREN)

FDG PET

France
University of Cincinnati

Active, not recruiting

Assessment of Investigational Positron Emission Tomography and Post-Processing Procedures Performed as Add-ons to Standard of Care Imaging

PET Imaging

United States
Pfizer

Terminated

Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib

Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis

United States, Japan
GE Healthcare

Terminated

Development of an Integrated Positron Emission Tomography/Magnetic Resonance (PET/MR) System, Accessories and Components

Indication for a PET CT Exam

United States
Sir Mortimer B. Davis - Jewish General Hospital

Enrolling by invitation

Fluorocholine PET/CT Basket Trial

Fluorocholine PET/CT

Canada
University of Cincinnati
National Cancer Institute (NCI); Ohio Third Frontier

Active, not recruiting

Validating Low FDG Dose PET/CT Compared to Current Standard of Care Dose PET/CT

PET/CT Imaging

United States
University Hospital Inselspital, Berne

Recruiting

Assessing Ultra-low Dose PET/CT and CT-less PET Using a Long Axial Field-of-view PET/CT System (ULD-PET)

PET/CT

Switzerland
Abdul Latif Jameel Poverty Action Lab
Massachusetts Institute of Technology; Aurora Health Care; Laura and John Arnold...

Completed

Clinical Decision Support (CDS) for Radiology Imaging

CT, MR, NM, and PET Image Orders

United States
GE Healthcare

Completed

Clinical Evaluation of an Integrated PET/MRI System (PET/MR_ZURICH)

Subjects With Clinical Indication for PET/CT

Switzerland
Washington University School of Medicine
Siemens Corporation, Corporate Technology

Recruiting

Gated and Non-Gated Dynamic PET/CT Imaging

Dynamic PET/CT Imaging

United States
Universitaire Ziekenhuizen KU Leuven

Completed

Study of Pain, Anxiety and Complications Related to Cannulation of Arteriovenous (AV) Fistula in Chronic Hemodialysis Patients

Fistula | Dialysis

Belgium
Institut Bergonié

Completed

Feasibility Study on the Contribution of Guided Puncture With Echoendoscopy (APOGEE)

Hypermetabolic Lymphadenopathy Mediastinum Lower, Posterior and Middle, Detected by PET-CT With 18F-FDG (PET)

France
Incyte Corporation

Completed

Alternative Dosing Strategy of Ruxolitinib in Patients With Myelofibrosis

Primary Myelofibrosis | Post-Polycythemia Vera Myelofibrosis | Post-Essential Thrombocythemia Myelofibrosis

United States
Assiut University

Not yet recruiting

Factors Affecting BAT Activation in PET/CT

Factors Affecting BAT Activation in PET/CT
Novartis Pharmaceuticals

Completed

A Clinical Study of Ruxolitinib in Patients With Primary Myelofibrosis (PM), Post-polycythemia Vera (PV) Myelofibrosis, or Post-essential Thrombocythemia (ET) Myelofibrosis

Primary Myelofibrosis (MF)

Japan
National Taiwan University Hospital

Unknown

Single Versus Multiple Fractionated SSRS for Spinal Metastases

Secondary Malignant Neoplasm of Spine

Taiwan
Royal Marsden NHS Foundation Trust
City, University of London

Unknown

Radiation Exposure Awareness From Patients Undergoing Nuclear Medicine Diagnostic Scans (REA)

FDG PET/CT | Skeletal Scintigraphy

United Kingdom
Curium PET France

Active, not recruiting

A Prospective Study on 18F-DCFPyL PET/CT Imaging in Biochemical Recurrence of Prostate Cancer (Python)

Prostate Cancer Recurrent

France
Alcon Research

Completed

DAILIES® AquaComfort Plus® Multifocal (MF) - Comparative Assessment of Visual Performance

Presbyopia
Xiaohua Zhu

Recruiting

Fluoride-labeled Boronophenylalanine PET Imaging in Patients With Solid Tumors

Solid Tumor, Adult

China
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Completed

Jaktinib for the Treatment of Ruxolitinib Intolerance of Myelofibrosis

Primary Myelofibrosis (PMF) | Post-polycythemia Vera Myelofibrosis(Post-PV MF) | Post-essential Thrombocythemia Myelofibrosis(Post-ET MF)

China
Turku University Hospital
SmithKline Beecham

Completed

Effects of Rosiglitazone and Metformin on Metabolism in Type 2 Diabetes (ROSI)

Type 2 Diabetes | Insulin Sensitivity

Finland
Innovative Medical

Completed

Evaluation Of Bilateral Tecnis Multifocal Versus ReSTOR 3D Intraocular Lenses

Cataract

United States
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Enhancing SUV Accuracy of PET/MR for Clinical Trial Qualification

Positron Emission Tomography-Magnetic Resonance (PET-MR)

United States
Novartis Pharmaceuticals

Completed

Asian Phase II Study of INC424 in Patients With Primary Myelofibrosis (MF), Post-PV MF or Post-ET MF

Primary Myelofibrosis (MF) | Post-Polycythemia Vera (PV) MF | Post-Essential Thrombocythemia (ET) MF

Taiwan, Japan, Korea, Republic of, China
Centre Hospitalier Universitaire Dijon

Recruiting

Evaluation of the Value of 18F-Fluoromisonidazole (18F-FMISO) Positron Emission Tomography Hypoxia Imaging in Idiopathic Pulmonary Fibrosis (FIPOXY)

Idiopathic Pulmonary Fibrosis

France
Incyte Corporation
Novartis

Completed

Study of the JAK Inhibitor Ruxolitinib Administered Orally to Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera-Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia-Myelofibrosis (PET-MF)

Myelofibrosis

France, United Kingdom, China, United States, Netherlands, Germany, Italy, Austria
SmartNuclide Biopharma
The First Affiliated Hospital of Soochow University

Recruiting

[68Ga]Ga-NOTA-SNA002 (PD-L1 PET Tracer) for PET/CT in Patients With Solid Tumors

Solid Tumor | Positron-Emission Tomography(PET)

China

Search clinical trials for: Post-essential thrombocythemia (PET-MF)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Russia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations